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Abstract
Background: Artemisinin-based combination therapies are recommended as first-line treatments for uncomplicated
falciparum malaria, but there is little evaluation of their efficacy and effects on uncomplicated malaria-associated
anaemia in children aged 2 years and under.
Methods: Parasitological efficacy and effects on malaria-associated anaemia were evaluated in 250 malarious children
aged 2 years and under, and efficacy was evaluated in 603 malarious children older than two but younger than 5 years
of age following treatment with artesunate-amodiaquine (AA) or artemether-lumefantrine (AL). Kinetics of the
disposition of parasitaemia following treatment were evaluated using a non-compartment model. Late-appearing
anaemia (LAA) was diagnosed using the following criteria: clearance of parasitaemia, fever and other symptoms
occurring within 7 days of starting treatment, adequate clinical and parasitological response on days 28–42,
haematocrit (HCT) ≥ 30 % at 1 and/or 2 weeks, a fall in HCT to < 30 % occurring at 3–6 weeks, absence of
concomitant illness at 1–6 weeks, and absence of asexual parasitaemia detected using both microscopy and
polymerase chain reaction (PCR) at 1–6 weeks.
Results: Overall, in children aged 2 years and under, the PCR-corrected parasitological efficacy was 97.2 % (95 %
CI 92.8–101.6), which was similar for both treatments. In children older than 2 years, parasitological efficacy was
also similar for both treatments, but parasite prevalence 1 day after treatment began was significantly higher, and
fever and parasite clearance times were significantly faster in the AA-treated children compared with the AL-treated
children. Declines in parasitaemia were monoexponential with an estimated elimination half-time of 1 h. Elimination
half-times were similar for both treatments. In children aged 2 years and under who were anaemic at presentation,
the mean anaemia recovery time was 12.1 days (95 % CI 10.6–13.6, n = 127), which was similar for both treatments.
Relatively asymptomatic LAA occurred in 11 children (4.4 %) aged 2 years and under, the recovery from which
was uneventful.
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Conclusion: This study showed that AA and AL are efficacious treatments for uncomplicated falciparum malaria in
Nigerian children aged 2 years and under, and that AA clears parasitaemia and fever significantly faster than AL in
children older than 2 years. Both treatments may cause a relatively asymptomatic LAA with uneventful recovery in a
small proportion of children aged 2 years and under.
Trials registration: Pan African Clinical Trial Registry PACTR201508001188143, 3 July 2015; PACTR201510001189370,
3 July 2015; PACTR201508001191898, 7 July 2015 and PACTR201508001193368, 8 July 2015 http://www.pactr.
org.
Keywords: Falciparum malaria, Malaria-related anaemia, Young children, Artemisinin-based combination
therapies, Nigeria
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Background
Artemisinin-based combination therapies (ACTs) have
remained efficacious since their adoption as first-line
treatments for uncomplicated Plasmodium falciparum
malaria [1]. In Nigeria, artemether-lumefantrine (AL)
and artesunate-amodiaquine (AA) were adopted as first-
line treatments in 2005 [2]. However, recent reports of
artemisinin resistance in P. falciparum malaria [3] in the
Greater Mekong subregion [4–9], and its declining respon-
siveness reported in Kenya [10] and Suriname [11], have
made it imperative to monitor, on a continuous basis, the
efficacy of ACTs for treating P. falciparum malaria globally.
Traditionally, in endemic areas, antimalarial efficacy
assessments have been carried out in children younger
than 5 years of age because of this age group’s relative
lack of antimalarial immunity [12]. However, it is un-
clear if very young children (≤2 years old) differ in
therapeutic responses from those older than two but
younger than 5 years of age. Additionally, there has
been little or no evaluation of the efficacy of these drug
combinations in children with uncomplicated falcip-
arum malaria who are aged 2 years and under. Such
information is necessary as it may aid in the early de-
tection of declining responsiveness of P. falciparum
malaria infections to ACTs in children, as well as help
guide appropriate responses.
In the present study, we analyzed the responsiveness
of P. falciparum infections to AA and AL in the 10-year
period since the adoption of these as first-line treat-
ments for uncomplicated falciparum malaria in Nigeria.
We compared the therapeutic responses to the two
ACTs in children aged 2 years and under with children
older than 2 years of age. In addition, we evaluated the
recovery from malaria-associated anaemia and de-
scribed late-appearing anaemia (LAA) in children aged
2 years and under.
Methods
Study sites
The study was conducted between October 2009 and
November 2010 at the following sites in Nigeria: Agbani
in Enugu State, Barkin Ladi in Plateau State, and Damboa
in Borno State (the eastern flank of the study sites); Ijede
in Lagos State and Makarfi in Kaduna State (the western
flank of the study sites); and in Sabo quarters of Ibadan,
Oyo State, located on the western flank between 2005
and 2015 (see Fig. 1).
In virtually all study locations, malaria is hyperen-
demic and transmission occurs all year round, however,
it is more intense during the rainy season, which lasts
from April to October. P. falciparum is the predominant
species, accounting for over 98 % of all infections [1, 13].
Children are more affected than adults and asymptomatic
infections more often occur in older school children aged
greater than 5 years and adults [13]. The details pertaining
to the larger studies conducted have been reported else-
where [14–20].
Study procedure
Specific study procedures have been described for each
study conducted before [14–20]. All enrolment proce-
dures are the same at all sites. Patients were eligible for
evaluation if they were: aged 6–24 months or 25–59
months, had symptoms compatible with acute uncom-
plicated P. falciparum malaria with a monoinfection ≥ 1
000 μL−1 of blood, no history of antimalarial drug inges-
tion in the 2 weeks prior to enrolment, absence of severe
malaria and obtained written informed consent from
parents or guardians.
Enrolled patients were randomized and received AL or
AA (co-formulated). Artemether-lumefantrine (Coartem®,
Novartis, Basel, Switzerland) was administered according
to body weight: patients weighing 5–14 kg received one
tablet; those weighing 15–24 kg received two tablets at
presentation (0 h), 8 h later, and at 24, 36, 48 and 60 h
after the first dose. Each tablet of AL contained 20 mg of
artemether and 120 mg of lumefantrine. Artesunate-
amodiaquine (Coarsucam®, Sanofi Aventis, France) was
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also administered according to body weight: patients
weighing from 4.5 to under 9 kg received one tablet of
25 mg/67.5 mg of a fixed-dose combination of artesunate/
amodiaquine respectively, those weighing 9 to under 18 kg
received one tablet of 50 mg/135 mg, and those weighing
18 to under 24 kg received one tablet of 100 mg/270 mg,
daily for 3 days. Children older than 2 years were treated
with AA or AL, as previously described [20].
All drugs were given orally. All doses of AA were
given by direct observed therapy. The doses of AL at
presentation (day 0, 0 h), and at 8, 24 and 48 h were ad-
ministered by direct observed therapy. Doses of AL at
36 and 60 h were given by parents/guardians at home.
Thick and thin blood films were obtained from each
child as soon as he/she came to the clinic, and the
slides were carefully labeled with the patients’ codes
and air-dried before being stained. The slides were
examined by light microscopy under an oil-immersion
objective lens at 1000× magnification by two inde-
pendent assessors who did not know the drug regimen
of the patients. A senior member of the study team
reviewed the slides if there was any disagreement be-
tween the two microscopists. In addition, the slides of
every fourth child were reviewed by the senior mem-
ber. Parasitaemia, asexual or sexual, was estimated by
counting the asexual and sexual parasites relative to
500 leukocytes, or 500 asexual or sexual forms, whichever
occurred first, in the thick films. Using this figure, the
parasite density was calculated assuming a leukocyte
count of 6 000 μL−1 of blood. A slide was considered
parasite negative if no asexual or sexual parasite was
detected after examination of 200 microscopic fields. A
clinical and parasitological evaluation was done on days
1–3 and on days 7, 14, 21 and 28 at all study sites,
7,814 children aged < 5 years old screened (2005 – 2015) 
3,650 in Ibadan (2005-2015)
1,297 (36%) with parasitaemia 
71 ≤ 2 years old
337 randomized* 
266 > 2 - < 5 years old 
AA  
(n = 31) 
2 - prematurely 
withdrawn from 
study 
3 - lost to follow-
up 
0 - withdrawn 
consent 
4,164 in 5 other study sites (2009 – 2010)
1,291 (31%) with parasitaemia 
201 ≤ 2 years old
574 randomized**
373 > 2 - < 5 years old 
AL  
(n = 40) 
AA  
(n = 143) 
AL  
(n = 123) 
AA  
(n = 99) 
AL  
(n = 102) 
AA  
(n = 196) 
AL  
(n = 177) 
128 113 94 95 187 175
1 - prematurely 
withdrawn from 
study 
3 - lost to follow-
up 
0 - withdrawn 
consent 
3 - prematurely 
withdrawn from 
study 
10 - lost to follow-
up 
2 - withdrawn 
consent 
2 - prematurely 
withdrawn from 
study 
6 - lost to follow-
up 
2 - withdrawn 
consent 
2 - prematurely 
withdrawn from 
study 
3 - lost to follow-
up 
0 - withdrawn 
consent 
1 - prematurely 
withdrawn from 
study 
6 - lost to follow-
up 
0 - withdrawn 
consent 
0 - prematurely 
withdrawn from 
study 
7 - lost to follow-
up 
2 - withdrawn 
consent 
0 - prematurely 
withdrawn from 
study 
2 - lost to follow-
up 
0 - withdrawn 
consent 
26# 35
Fig. 1 Study profile. AA, artesunate-amodiaquine; AL, artemether-lumefantrine, *follow-up was for 42 days, **follow-up was for 28 days, #number
of children that completed follow-up period
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except in Ibadan where additional follow-up was done
on days 35 and 42.
Cure rates on day 28 were adjusted based on the
polymerase chain reaction (PCR) genotyping results of
patients’ recurrent parasitaemia paired samples 7 days
after starting treatment, as previously described [20].
An asexual parasite reduction ratio (PRR) [21] was
defined as the ratio of day 0/day 2 parasitaemia (and
for convenience, referred to as PRRD2): that is, PRRD2
¼ Parasitaemia on day 0Parasitaemia on day 2 . The asexual PRR on day 1 (PRRD1)
was defined as the ratio of day 0/day 1 parasitaemia: that
is, PRRD1 ¼ Parasitaemia on day 0Parasitaemia on day 1.
Kinetics of the disposition of parasitaemia following
treatment
In 20 children aged 2 years and under, enrolled between
2008 and 2015 at the Ibadan study site, clinical and
parasitological evaluations were done at the following
times: at 0, 1, 2, 4, 6, 8 and 24 h, and on days 2–7, 14,
21, 28, 35 and 42. The kinetics of the time-course of the
parasitaemia was estimated using a non-compartmental
model, as previously described [17, 22].
Haematological evaluation
Capillary blood collected before and during follow-up was
used to measure haematocrit (HCT) using a microhaema-
tocrit tube and microcentrifuge (Hawksley, Lancing, UK).
Anaemia was defined as HCT < 30 %, and was classified
as either mild, moderate or severe if HCT was 21–29,
15–20 or < 15 %, respectively. Anaemia recovery time
(AnRT) (in anaemic patients) was defined as the time
elapsed from drug administration to getting a HCT
value ≥ 30 % [18, 20, 23, 24].
Diagnosis of LAA after administering ACTs
In children aged 2 years and under, a diagnosis of LAA
was made if the following criteria were met following
the initiation of ACTs: clearance of parasitaemia, fever
and other symptoms occurring within seven days of
starting treatment, adequate clinical and parasitological
response (ACPR) [25, 26] on days 28–42, HCT ≥ 30 % at
1 and/or 2 weeks, a fall in HCT to < 30 % occurring at
3–6 weeks, absence of concomitant illness at 1–6 weeks,
and absence of asexual parasitaemia detected using both
microscopy and PCR at 1–6 weeks (Sowunmi et al., 2015,
unpublished, submitted for publication).
Statistical analysis
Data were analyzed using the Epi Info™ version 6 soft-
ware (Centers for Disease Control and Prevention,
Atlanta, GA, USA) [27] and the statistical program SPSS
for Windows version 20.0 (SPSS Inc., Chicago IL, USA)
[28]. Variables considered in the analysis were related to
the densities of P. falciparum asexual and sexual forms.
Proportions were compared by calculating χ2 using Yates’s
correction, Fisher’s exact or Cochran-Mantel-Haenszel
tests. Normally distributed, continuous data were com-
pared using the Student’s t-test and analysis of variance
(ANOVA). Data not conforming to a normal distribution
were compared using the Mann-Whitney U test and the
Kruskal-Wallis H test (or by Wilcoxon rank sum test).
The relationship between two continuous variables was
assessed using the Spearman’s rank correlation coefficient.
The cumulative risk of parasite reappearance was calcu-
lated by survival using the Kaplan-Meier method. P-values
of < 0.05 were considered statistically significant. Data
were double-entered serially using patients’ codes and
were only analyzed at the end of the study.
Ethical clearance
The study protocol was approved by the Ministry of
Health, Ibadan and the National Health Research Ethics
Committee, Abuja, Nigeria. Written informed consents
were obtained from parents/guardians of the children.
Results
Patient characteristics at enrolment
During the study period, a total of 911 children aged
younger than 5 years from five geographical areas of
Nigeria who had parasitaemia were enrolled and treated
with AA or AL. Of these, 272 (30 %) were aged 2 years
and under (see Fig. 1) and of those, 250 were evaluated
in this study. The characteristics of the children at enrol-
ment in each study site and for each year of study are
shown in Table 1.
Children enrolled in Ibadan between 2005 and 2010
but not between 2011 and 2015, were significantly older
and had a significantly higher body temperature and en-
rolment parasitaemia compared with children enrolled
at the other study sites. Children enrolled in Barkin Ladi
had a significantly higher HCT at enrolment. In children
aged 2 years and under, anaemia at presentation was
more significantly common in children older than 1 year
of age compared with children aged 1 year and under
(103/185 versus 25/65; P <0.05).
Therapeutic responses
Children ≤ 2 years old
In children aged 2 years and under, the overall PCR-
corrected ACPR on day 28 was 97.2 % (95 % CI 92.8–
101.6). Overall, for both treatments and for all study
sites, the PCR-uncorrected ACPR on day 28 was 234/
250 (94 %) and the PCR-corrected ACPR on day 28 was
234/247 (95 %) (see Table 2).
Table 3 shows the therapeutic responses to AA and
AL for each study site. For AA, the overall PCR-
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Temperature (°C) Haematocrit (%) Degree of anaemia Parasitaemia (μL−1)
M/F Mean ± sd
(Range)






No. >37.4 °C No. ≥40 °C Mean ± sd
(Range)






47 26/21 1.7 ± 0.4
(0.7–2)






39 2 28.3 ± 4.5
(20–38)





24 16/8 1.5 ± 0.5
(0.5–2)
7 9.9 ± 3.9
(5–20)
- 37.9 ± 0.6
(37.5–39.3)
24 - 27.9 ± 5.9
(14–36)





57 24/33 1.3 ± 0.5
(0.5–2)
20 9.9 ± 1.7
(5–17)
- 37.6 ± 1.1
(35.6–40.3)
30 1 27.3 ± 4.3
(18–40)





41 24/17 1.4 ± 0.4
(0.5–2)
15 8.4 ± 1.6
(5–12)
- 37.9 ± 1
(36–39.4)
29 - 29.4 ± 5.1
(16–37)





28 18/10 1.4 ± 0.4
(0.6–2)
6 9.2 ± 1.6
(5–12)
- 38.1 ± 1.4
(36–40.3)
18 4 28.9 ± 4.8
(19–38)





39 20/19 1.6 ± 0.5
(0.6–2)






30 1 30.7 ± 4.2
(22–40)





14 11/3 1.4 ± 0.6
(0.5–2)






9 1 29 ± 4.1
(22–37)





250 139/111 1.5 ± 0.5
(0.5–2)






179 9 28.7 ± 4.8
(14–40)
127 112 14 1 13,714
(1000–304,500)
16
P value - 0.14 0.03 0.03 0.001 0.83 0.01 0.02 0.29 0.03 0.02 0.85 0.99 - <0.0001 0.11
sd standard deviation














corrected ACPR on day 28 was 99.3 % (95 % CI 97.6–
101) at all sites. The PCR-uncorrected ACPR on day 28
was 112/120 (93 %) and the PCR-corrected ACPR on
day 28 was 112/116 (97 %). The PCR-corrected ACPR
was similar at all sites. For AL, the overall PCR-
corrected ACPR on day 28 was 96.9 % (95 % CI 91.5–
102.3) at all sites. The PCR-uncorrected ACPR on day
28 was 122/130 (94 %) and the PCR-corrected ACPR on
day 28 was 122/127 (96 %). The PCR-corrected ACPR
was similar at all sites. Overall, the PCR-corrected ACPR
on day 28 was similar for both treatments (99.3 % versus
96.9 % for AA and AL, respectively; P >0.05).
No child had early treatment failure, however, late
parasitological failure (LPF) occurred in 16 children,
who were all enrolled between 2005 and 2010. There
was no significant difference in the proportions of
children with LPF in the two treatment groups (8/120
children treated with AA versus 8/130 children treated
with AL, P >0.05). The proportion of children with LPF
was also similar in infants and non-infants, and was not
Table 2 Overall efficacy of artesunate-amodiaquine or artemether-lumefantrine in ≥2 years old malarious children according to
study sites
PCR uncorrected PCR corrected
Site (Year) ACPR_u Failure_u Total ACPR_c Recrudescence Total % Recrudescence
Ibadan (2005–2010) 47 0 47 47 0 47 -
Damboa (2009–2010) 24 0 24 24 0 24 -
Agbani (2009–2010) 50 7 57 50 6 56 10.7
Makarfi (2009–2010) 40 1 41 40 0 40 -
Ijede (2009–2010) 27 1 28 27 0 27 -
Barkin Ladi (2009–2010) 32 7 39 32 3 35 8.6
Ibadan (2011–2015) 14 0 14 14 0 14 -
Total (2005–2015) 234 16 250 234 9 247 3.6
PCR polymerase chain reaction, ACPR_u adequate clinical and parasitological response uncorrected, ACPR_c adequate clinical and parasitological response
corrected, Failure_u treatment failure uncorrected
Table 3 Efficacy of artesunate-amodiaquine or artemether-lumefantrine in ≥2 years old malarious children according to study site
and year of enrolment
Site (Year) PCR uncorrected PCR corrected
ACPR_u Failure_u Total ACPR_c Recrudescence Total % Recrudescence
Artesunate-amodiaquine
Ibadan (2005–2010) 15 0 15 15 0 15 -
Damboa (2009–2010) 17 0 17 17 0 17 -
Agbani (2009–2010) 23 5 28 23 4 27 14.8
Makarfi (2009–2010) 17 0 17 17 0 17 -
Ijede (2009–2010) 14 0 14 14 0 14 -
Barkin Ladi (2009–2010) 15 3 18 15 0 15 -
Ibadan (2011–2015) 11 0 11 11 0 11 -
Total (2005–2015) 112 8 120 112 4 116 3.4
Artemether-lumefantrine
Ibadan (2005–2010) 32 0 32 32 0 32 -
Damboa (2009–2010) 7 0 7 7 0 7 -
Agbani (2009–2010) 27 2 29 27 2 29 6.9
Makarfi (2009–2010) 23 1 24 23 0 23 -
Ijede (2009–2010) 13 1 14 13 0 13 -
Barkin Ladi (2009–2010) 17 4 21 17 3 20 15
Ibadan (2011–2015) 3 0 3 3 0 3 -
Total (2005–2015) 122 8 130 122 5 127 3.9
PCR polymerase chain reaction, ACPR_u adequate clinical and parasitological response uncorrected, ACPR_c adequate clinical and parasitological response
corrected, Failure_u treatment failure uncorrected
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related to their anaemia status at presentation (4/65
versus 12/185 in infants and non-infants, respectively,
P >0.05; and 10/127 versus 6/123 in anaemic and non-
anaemic children, respectively, P >0.05).
Recrudescence occurred in nine children (six from
Agbani and three from Barkin Ladi). Recrudescence
occurred in four children treated with AA and five chil-
dren treated with AL. Overall, mean time to recrudes-
cence was 21.8 ± 5.5 days (range 14–28) and was similar
in children treated with AA and AL (22.8 ± 6.7 days
[range 14–28] versus 21 ± 4.9 days [range 14–28]; P =
0.66). The probabilities of the reappearance of asexual
parasitaemia after treatment were similar between AA and
AL (log-rank statistic = 0.006, P = 0.94, see Fig. 2a). The
probabilities of reappearance of asexual parasitaemia after
treatment with both drugs were similar in infants and
non-infants (log-rank statistic = 0.03, P = 0.86, see Fig. 2b).
Table 4 shows that other measures of therapeutic re-
sponses were similar in children treated with AA and
AL. Only three children (two on AA and one on AL) ex-
hibited parasitaemia on day 3.
Children ≤ 2 years old at the Ibadan study site
Overall, the therapeutic responses of 61 children aged
2 years and under were evaluated during the 10-year
period since AA and AL were introduced as first-line
treatments for malaria in Nigeria (47 children from 2005
to 2010 and 14 children from 2011 to 2015). Of the 61
children, 26 were treated with AA and 35 with AL. Be-
cause of the small number of patients, therapeutic re-
sponses over the years were merged for both treatments.
Baseline parameters at enrolment were similar for both
AA and AL. Mean age (1.6 ± 0.5 years versus 1.6 ±
0.4 years, P = 0.43) and geometric mean parasitaemia
(28,143 μL−1 [1614–128,976] versus 29,629 μL−1 [4938–
304,500]; P = 0.68) were similar for the AA and AL treat-
ment groups, respectively. Therapeutic responses were
also similar for the two treatments: ACPR on day 28
(26/26 versus 35/35), geometric mean PRR (1.9 × 104
[range 2.2 × 102–1.3 × 105] versus 4.9 × 103 [range 1.7 ×
100–2.9 × 105]; and 2.8 × 104 [range 1.6 × 103– 1.3 × 105]
versus 2.8 × 104 [range 1.9 × 103–3.0 × 105] one and
2 days after treatment began, respectively) and fever
clearance time (FCT) (1.2 ± 0.1 standard error of mean,
SEM [range 1–4, n = 22] versus 1.5 ± 0.2 SEM [1–7, n =
26]). The parasite clearance time (PCT) was significantly
shorter for children treated with AA than for those
treated with AL (1.1 ± 0.3 [range 1–2] versus 1.3 ± 0.5
[range 1–3]).
During the two study periods (2005–2010 and 2011–
2015), the proportions of children with ACPR on day 28
(47/47 versus 14/14), parasite prevalence 1 day after treat-
ment began (8/47 versus 3/14), PRRs (9.0 × 103 [range
1.7 × 100–2.9 × 105] versus 7.4 × 103 [range 1.2 × 102–1.1 ×
105], and 3.1 × 104 [range 1.6 × 103–3.0 × 105] versus 2.0 ×
104 [range 1.9 × 103–1.1 × 105] 1 and 2 days after treatment
began, respectively), FCTs (1.4 ± 0.2 SEM [range 1–7, n =
39] versus 1.3 ± 0.3 SEM [1–4, n = 9]), and PCTs (1.2 ± 0.4
[range 1–2] versus 1.3 ± 0.6 [range 1–3]) were similar.
Therapeutic responses according to treatment and age
groups
Comparison of therapeutic responses in children ≤ 2
and > 2– < 5 years
Comparing all children treated with AA or AL showed
that the PRRs one and 2 days after treatment began were
significantly higher in children older than 2 years but
younger than 5 years of age than in children aged 2 years
and under (1.1 × 103 [range 3.2 × 10−1–2.1 × 106] versus
Fig. 2 Kaplan-Meier survival estimates of asexual parasitaemia (a) after
treatment of≤ 2 years old children with AA (blue line) or AL (green line;
log-rank statistic = 0.006; P = 0.94) and (b) in infants (green line) and
non-infants (blue line) treated with AA or AL (log-rank statistic = 0.03;
P = 0.86). AA, artesunate-amodiaquine; AL, artemether-lumefantrine
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5.5 × 102 [range 1.1 × 10−1–2.9 × 105], P = 0.01; and 1.9 ×
104 [range 1.7 × 101–2.1 × 106] versus 1.1 × 104 [range
1.9 × 101–3.0 × 105]; P < 0.0001; respectively). Fever clear-
ance time and AnRT were significantly lower in children
aged older than 2 years but younger than 5 years com-
pared with children aged 2 years and under (1.1 days
[95 % CI 1.1–1.2, n = 179] versus 1.3 days [95 % CI 1.2–
1.4, n = 450], P = 0.02; and 10.7 days [95 % CI 9.6–11.7, n
= 179] versus 12.8 days [95 % CI 11.1–14.4, n = 450], P
<0.03; respectively). Other measures of therapeutic re-
sponses, for example, the PCR-corrected ACRP on day 28
(234/244 [96.3 %] versus 559/589 [94.9 %], P > 0.05); para-
site prevalence 1 day after treatment began (126/250
[50 %] versus 278/603 [46 %], P > 0.05); and parasite posi-
tivity rate on day 3 (3/250 versus 7/603, P > 0.05), respect-
ively, were similar in children aged 2 years and under and
those older than 2 years but younger than 5 years.
AA: In children younger than 1 year old (n = 29) and
those 1 year old and above (n = 91) who were treated
with AA, no significant differences were observed in the
therapeutic responses to the drug. In children aged
2 years and under (n = 120) and those older than 2 years
but younger than 5 years (n = 315) who were treated
with AA, PRRs 1 and 2 days after treatment began were
significantly higher. The FCT was significantly lower in
children older than 2 years but younger than 5 years of
age compared with children aged 2 years and under
(see Table 5).
AL: In children younger than 1 year (n = 46) and those
1 year or above (n = 84) who were treated with AL, the
parasite prevalence 1 day after treatment began and
PCTs were significantly lower in children younger than
1 year compared with children 1 year or older. In chil-
dren aged 2 years and under (n = 130) and those older
than 2 years but younger than 5 years (n = 288) who
were treated with AL, the PRR 2 days after treatment
began was significantly lower in children older than
2 years but younger than 5 years compared with children
aged 2 years and under (see Table 6).
Comparison of therapeutic responses in children aged
> 2– < 5 years
Three hundred and fifteen children and 288 children
older than 2 years of age were treated with AA and AL,
respectively. The parasite prevalence 1 day after treat-
ment began (124/315 [39 %] children versus 154/288
[53 %] children, P < 0.05), FCT (1.1 ± 0.3 days [95 % CI
1–1.1 n = 234] versus 1.2 ± 0.7 days [95 % CI 1.1–1.3, n
= 222]; P = 0.002), and PCT (1.4 ± 0.6 days [95 % CI 1.4–
1.5] versus 1.6 ± 0.6 days [95 % CI 1.5–1.7]; P < 0.05)
were significantly lower in children treated with AA
compared with those treated with AL. The PRR 1 day
after treatment began was significantly higher in children
treated with AA compared with those treated with AL
(1.9 × 103 [range 3.2 × 10−1–1.1 × 106] versus 5.6 × 102
[range 9.5 × 10−1–2.1 × 106]; P < 0.05). However, the
PCR-corrected ACPR on day 28 (294/310 [95 %] versus
265/279 [95 %] for AA and AL, respectively; P >0.05)
and the AnRT (10.4 days [95 % CI 9–11.8] versus 11 days
[95 % CI 9.4–12.6] for AA and AL, respectively; P >0.05)
were similar for the two treatment groups.
Kinetics of the disposition of parasitaemia
In children aged 2 years and under, the kinetics of the
disposition of parasitaemia were evaluated in 20 children
with the following demographic and clinical characteris-
tics: mean age = 1.6 years (range 0.6–2), male/female ratio
13:7, mean duration of illness = 2.3 days (range 1–4),
Table 4 Other measures of treatment outcomes in children≤ 2 treated with artesunate-amodiaquine or artemether-lumefantrine
ALL (250) Artesunate-amodiaquine (120) Artemether-lumefantrine (130) P value
Parasite prevalence on day 1 126 58 68 0.62
Parasite positivity rate on day 3 3 2 1 0.61
PRRD1
Geometric mean 5.5 × 102 5.6 × 102 5.4 × 102 0.79
Range 1.1 × 10−1–2.9 × 105 1.1 × 10−1–1.3 × 105 4.1 × 10−1–2.9 × 105
PRRD2
Geometric mean 1.1 × 104 1.0 × 104 1.1 × 104 0.7
Range 1.9 × 101–3.0 × 105 1.9 × 101–1.3 × 105 2.6 × 101–3.0 × 105
Fever clearance time (day)
Mean 1.3 1.3 1.4 0.83
95 % CI 1.2–1.5 1.1–1.5 1.1–1.6
Parasite clearance time (day)
Mean 1.6 1.5 1.6 0.46
95 % CI 1.5–1.7 1.4–1.7 1.5–1.7
PRRD1 parasite reduction ratio 1 day after treatment started, PRRD2 parasite reduction ratio 2 days after treatment started, ALL all children
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mean body temperature = 38.1 °C (range 36.6–39.9 °C,
no. with > 37.4 °C = 12), mean HCT = 28 % (range 20–38,
no. with < 30 % = 12), geometric mean asexual parasit-
aemia of 48,580 μL−1 (range 3625–288,461; no. with >
100,000 μL−1 = 5; no. with > 250,000 μL−1 = 1), mean FCT
= 1.1 days (range 1–2), mean PCT = 1.2 days (range 1–3),
and mean AnRT 13.5 days (range 1–28).
Overall, a monoexponential decline of parasitaemia
was observed, with an estimated mean elimination half-
time (t½el) of 1 h (95 % CI 0.9–1.1) (see Fig. 3a). The es-
timated mean t½el values were similar for AA (1 h, 95 %
CI 0.9–1.2)- and AL (0.9 h, 95 % CI 0.9–1.7)- treated
children (P >0.05) (see Fig. 3b). In children aged 1 year
old and under (n = 3) and those older than 1 year (n =
17), the estimated mean elimination half-times were
0.9 h (95 % CI 0.2–1.5) and 1 h (95 % CI 0.9–1.6), re-
spectively; they were similar (P >0.05) (see Fig. 3c).
Estimated mean elimination half-times were also similar
in children with enrolment parasitaemia ≥ 100 000 μL−1
and those with < 100 000 μL−1 (1 h [95 % CI 0.6–1.4, n
= 5] versus 1 h [95 % CI 0.9–1.1, n = 15]; P >0.05, re-
spectively) and in anaemic and non-anaemic children at
presentation (1 h [95 % CI 0.8–1.1, n = 11] versus 1 h
[95 % CI 0.7–1.2, n = 9]; P >0.05, respectively).
Relationship between elimination half-time of parasitaemia
and PCT
The relationship between the elimination half-time of
parasitaemia and PCT in the same patients was evalu-
ated in 20 children aged 2 years old and under. The
mean elimination half-time of parasitaemia was 1 h
(95 % CI 0.9–1.1) and PCT was 1.1 day (95 % CI 1–
1.2). A significantly positive correlation was observed
between elimination half-time of parasitaemia and
Table 5 Therapeutic outcomes based on age group in children treated with artesunate-amodiaquine
Parameter ≤2 years <5 years
<1 year (n = 29) ≥1 year (n = 91) P value ≤2 years (n = 120) ≥2– < 5 years (n = 315) P value
Haematocrit (%)
Mean 28.8 28.4 0.63 28.5 30.5 <0.0001
95 % CI 27.4–30.3 27.2–29.5 27.6–29.4 30–31.1
No <30 % 13 55 0.21 68 117 <0.0001
Parasitaemia (μL−1)
Geometric mean 13,807 11,883 0.55 12,322 23,733 <0.0001
Range 1,018–114,504 1,000–128,976 1,000–128,976 1,000–1,125,000
No. >100,000 μL−1 2 7 1.0 9 55 0.01
No. >250,000 μL−1 0 0 - 0 12 -
ACPR on day 28 (%) 26/27 (96) 86/89 (97) 1.0 112/116 (97) 294/310 (95) 0.48
Parasite prevalence on day 1 (%) 18 (62) 40 (44) 0.14 58 (48) 124 (39) 0.11
PRRD1
Geometric mean 3.8 × 102 6.4 × 102 0.41 5.4 × 102 1.9 × 103 0.001
Range 3.9 × 100–1.1 × 105 1.1 × 10−1–1.3 × 105 1.1 × 10−1–1.3 × 105 3.2 × 10−1–1.1 × 106
PRRD2
Geometric mean 1.0 × 104 1.0 × 104 0.56 1.0 × 104 1.9 × 104 0.001
Range 3.9 × 101–1.1 × 105 9.5 × 101–1.3 × 105 1.9 × 101–1.3 × 105 5.3 × 101–1.1 × 106
Parasite positivity rate on day 3 0 3 - 2 2 0.31
Fever clearance time (day)
Mean 1.3 1.3 0.79 1.3 1.1 0.005
95 % CI 1–1.6 1–1.7 1.1–1.5 1–1.1
Parasite clearance time (day)
Mean 1.7 1.5 0.06 1.5 1.4 0.11
95 % CI 1.5–1.9 1.4–1.6 1.4–1.6 1.4–1.5
Anaemia recovery time (day)
Mean 12.1 12.5 0.91 12.4 10.4 0.12
95 % CI 6–18.2 9.9–15.1 10.1–14.7 9–11.8
ACPR adequate clinical and parasitological response, PRRD1 parasite reduction ratio 1 day after treatment started, PRRD2 parasite reduction ratio 2 days after
treatment started
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PCT in the same patients (r = 0.64, P <0.05), however,
no correlation was observed between elimination half-
time of parasitaemia and PRRs 1 or 2 days after treat-
ment began (r = 0.42, P >0.05 and r = 0.21, P >0.05,
respectively).
Adverse events
Adverse events were carefully monitored at the Ibadan
study site. Thirteen of the 61 children aged 2 years and
under (8/26 on AA and 5/35 on AL) reported at least
one adverse event within 1 week of starting treatment.
There was no significant difference in the proportions of
children reporting adverse events between the two treat-
ment groups (P >0.05). Overall, fever (n = 7) and cough
(n = 7) were the most frequently reported adverse events
in children treated with AA and AL. Abdominal pain
(n = 1) and weakness (n = 1) were the least reported
adverse events; they were reported only in the group
treated with AA. Almost all the reported adverse events
occurred in children aged older than 1 year.
Fifty-five out of 241 children older than two but
younger than 5 years (40/128 on AA and 15/113 on
AL) reported at least one adverse event within 1 week
of starting treatment. There was a significant differ-
ence in the proportions of children reporting adverse
events between the two treatment groups (P <0.05).
Overall, there was no significant difference in the re-
ported adverse events in those aged 2 years and under
and those older than two but younger than 5 years old
(P >0.05).
Overall, fever (n = 29) and cough (n = 23) were the
most frequently reported adverse events in children
treated with AA and AL. Weakness (n = 4) was the least
reported adverse event.
Table 6 Therapeutic outcomes based on age group in children treated with artemether-lumefantrine
Parameter ≤2 years (n = 130) <5 years (n = 418)
<1 year (n = 46) ≥1 year (n = 84) P value ≤2 years (n = 130) ≥2– < 5 years (n = 288) P value
Haematocrit (%)
Mean 28.9 28.9 0.96 28.9 29.9 0.05
95 % CI 27.4–30.3 28–29.8 28.1–29.7 29.3–30.5
No <30 % 19 40 0.61 59 129 0.99
Parasitaemia (μL−1)
Geometric mean 11,981 17,207 0.16 15,138 23,001 0.003
Range 1,000–304,500 1108–288,461 1,000–305,500 1,030–2,124,000
No. >100,000 μL−1 1 6 0.43 7 50 0.002
No. >250,000 μL−1 1 1 1.0 2 8 0.73
ACPR on day 28 (%) 45/46 (98) 77/81 (95) 0.65 122/127 (96) 265/279 (95) 0.82
Parasite prevalence on day 1 18 (39) 60 0.04 68 (52) 154 (53) 0.91
PRRD1
Geometric mean 9.1 × 102 4.0 × 102 0.31 5.4 × 102 5.6 × 102 1.0
Range 1.7 × 100–8.7 × 104 4.1 × 10−1–2.9 × 105 4.1 × 10−1–2.9 × 105 9.5 × 10−1–2.1 × 106
PRRD2
Geometric mean 1.1 × 104 1.2 × 104 0.51 1.1 × 104 1.8 × 104 0.004
Range 3.2 × 101–3.0 × 105 2.6 × 101–2.9 × 105 2.6 × 101–3.0 × 105 1.7 × 101–2.1 × 106
Parasite positivity rate on day 3 0 1 - 1 1 0.53
Fever clearance time (day)
Mean 1.2 1.3 0.64 1.3 1.2 0.4
95 % CI 1.1–1.4 1–1.6 1.1–1.5 1.1–1.3
Parasite clearance time (day)
Mean 1.4 1.7 0.01 1.6 1.6 0.92
95 % CI 1.3–1.6 1.6–1.8 1.5–1.7 1.5–1.7
Anaemia recovery time (day)
Mean 15.3 12.5 0.29 13.2 11 0.12
95 % CI 10.6–20.1 9.7–15.3 10.9–15.6 9.4–12.6
ACPR adequate clinical and parasitological response, PRRD1 parasite reduction ratio 1 day after treatment started, PRRD2 parasite reduction ratio 2 days after
treatment started
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Recovery from anaemia
In children aged 2 years and under, anaemia was present
at enrolment in 127 children, and was mild, moderate or
severe in 112 (88 %), 14 (11 %) and 1 (1 %) children, re-
spectively. All but 13 children with anaemia at presenta-
tion recovered from their anaemia. Of the 13 children
who did not recover from their anaemia, 10 and three
children had mild and moderate anaemia, respectively. In
the 114 children who recovered from anaemia, the mean
AnRT was 12.1 days (95 % CI 10.6–13.6) and was similar
for the two treatment groups (12.2 days [95 % CI 9.9–
14.4, n = 60] versus 12.1 days [95 % CI 10.0–14.2, n = 54]
in AA- and AL-treated children, respectively [P >0.05]).
The AnRT was also similar in children aged 1 year and
under and those aged 1 year and over (13.1 days [95 % CI
9.7–16.5, n = 23] versus 11.9 days [95 % CI 10.1–13.6, n =
91]; P >0.05). Overall, the mean AnRT was significantly
longer in children with high enrolment parasitaemia
(≥100,000 μL−1) compared with those with low enrolment
parasitaemia (<100,000 μL−1) (19.1 days [95 % CI 10.5–
27.7, n = 7] versus 11.7 days [95 % CI 10.1–13.2, n = 107];
P = 0.02). A significantly positive correlation was observed
between AnRT and enrolment parasitaemia (r = 0.24, P
<0.05, n = 114), but there was no correlation between
AnRT and age (r = 0.15, P <0.05, n = 114) or HCT at pres-
entation (r = 0.11, P >0.05, n = 114) in the same patients.
Late-appearing anaemia following treatment
Eleven children aged 2 years and under (4.4 %) had LAA
(see Table 7). The mean elapsed time from the start of
treatment to appearance of late anaemia was 24.2 days
(range 21–28 days). None of the 11 children reported a
symptom at the time of LAA, but one child had a body
temperature of 39.5 °C at the time of appearance of late
anaemia. Three out of five children treated with AA
had > 11 mg/kg total dose of artesunate. Five children
did not recover from their LAA; these children were
followed up for 28 days.
Discussion
In this study, both AA and AL were proved to be effect-
ive treatments for uncomplicated falciparum malaria, as
evidenced by a PCR-corrected parasitological efficacy of
over 96 %. Both treatments were similar in their thera-
peutic efficacy. In children older than 2 years of age,
both treatments rapidly reduce parasitaemia and fever
compared with children aged 2 years and below. These
findings suggest that therapeutic responses to both
ACTs were not uniform across the age range of below
5 years and may be influenced by age. Children older
than 2 years may possess some relative degree of
immunity compared with very young children.
Among the children older than 2 years, AA was super-
ior in clearing parasitaemia and fever. This would sug-
gest that the superior efficacy of AA over AL in clearing
parasitaemia and fever in children younger than 5 years
of age in this endemic area [17, 18, 20] can, to a large
extent, be attributable to the effects of AA on parasit-
aemia and fever clearance in children older than 2 years.
Children older than 2 years form the bulk of the chil-
dren under 5 years of age that are usually included in
therapeutic efficacy studies in endemic areas. The small
number of patients (3/250 children ≤ 2 years and 7/603
children >2– < 5) who exhibited parasite positivity on
day 3 indicates that there is no evidence for slow clear-




Fig. 3 Semilog plots of parasitaemia versus time (a) in all, (b) in
AA (blue) and AL (green)-treated children and (c) in ≤ 1-year olds
(blue) and > 1-year olds (green). [AA, artesunate-amodiaquine; AL,
artemether-lumefantrine]
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LAnRT Parasite reduction ratio (PRR) Total of mg/kg dose of AA Total of mg/kg dose of AL
Day 1 Day 2 Artesunate Amodiaquine Artemether Lumefantrine
124 (M, 2y) 2010 12,648 25 AL 2 28 [28] 28 NAc 1.2 × 101 1.3 × 104 NA NA 10.9 65.5
15 (M, 1.2y) 2008 72,815 27 AL 1 28 [28] 21 14 7.3 × 104 7.3 × 104 NA NA 17.4 102
46 (M, 0.8y) 2015 16,979 27 AA 1 29 [21] 21 7 1.7 × 104 1.7 × 104 15 40.5 NA NA
58 (M, 2y) 2010 19,647 28 AL 4 28 [28] 28 NAc 7.6 × 100 2.5 × 102 NA NA 8.6 51.4
15 (M, 1y) 2014 29,714 30 AL 1 29 [28] 28 7 3.0 × 104 3.0 × 104 NA NA 8.6 51.4
100 (M, 1.3y) 2010 118,344 30 AL 2 29 [21] 21 7 3.5 × 101 1.2 × 105 NA NA 13.3 80
64 (F, 1.9y)a 2010 76,000 30 AA 2 29 [28] 28 NAc 5.5 × 101 7.6 × 104 14.3 38.6 NA NA
8 (F, 1y) 2010 25,242 30 AA 2 28 [28] 28 NAc 2.4 × 102 2.5 × 104 10.7 28.9 NA NA
40 (F, 2y) 2010 1,652 30 AA 1 28 [21] 21 7 1.7 × 103 1.7 × 103 9.4 25.3 NA NA
911 (M, 1.9y) 2011 2,924 30 AA 1 28 [21] 21 14 2.9 × 103 2.9 × 103 12.5 38.3 NA NA
43 (M, 1.3y) 2010 1,301 31 AL 1 27 [28] 21 NAc 1.3 × 103 1.3 × 103 NA NA 13.3 80
Mean
Age (1.5y) 15,569b 28.9 1.6 28.3 24.2 9.3 6.6 × 102 1.0 × 104 12.4 34.3 12 71.7
HCT haematocrit, PCT parasite clearance time, M male, F female, AA artesunate-amodiaquine, AL artemether-lumefantrine, LAA late-appearing anaemia, LAnRT time to recovery from late-appearing anaemia, NA
not applicable
achild with fever of 39.5 °C on day 28
bGeometric mean parasitaemia














this endemic area. The low parasite positivity on day 3 is
in contradiction to the situation in the Greater Mekong
subregion, where parasite positivity on day 3 is high in
children treated with artemisinin [3, 7].
The monoexponential declines of parasitaemia indi-
cated that the disposition of parasitaemia following
treatment with both ACTs is a first-order process. The
parasitaemia elimination half-time of 1 h provides a
baseline for which future changes in parasite population
in vivo and in vitro susceptibility profile in very young
children from this endemic area may be measured or
compared. It is noteworthy that the elimination half-
time of parasitaemia of 1 h is considerably lower than
the 5.5 h reported in areas in the Greater Mekong sub-
region where resistance to artemisinin has emerged [9].
Reported adverse events following treatment were few,
and were similar for the two ACTs. The relative lack of
reported adverse events in very young children can be
attributed to their inability to name them. In children
older than 2 years, the reported adverse events were sig-
nificantly more frequent in those children treated with
AA compared with those treated with AL. This finding
is similar to a recent study conducted in older patients,
where reported adverse events were more frequent in
those treated with AA compared with AL [29].
Virtually all children who were anaemic at presenta-
tion recovered from their anaemia within 2 weeks of
starting treatment, a time similar to that previously re-
ported in a cohort study of children aged younger than
5 years [20]. An interesting finding was the relatively
asymptomatic nature of LAA, which occurred in 4 % of
very young children. It has been reported that symptom-
atic delayed haemolytic anaemia can occur following
intravenous artesunate treatment of severe malaria in
immunological naïve patients [30–32] and in African
children [33], and is attributable to a delayed destruction
of once-parasitized red blood cells from which the para-
sites have been removed by ‘pitting’ during passage
through the spleen [34]. The relatively asymptomatic
nature of and the paucity of signs during LAA may be
responsible for the failure to recognize LAA as a ‘saving’
effect of ACTs due to rapid clearance of parasitaemia
and conservation of HCT. The children who did not re-
cover from their LAA were followed up for 28 days. It is
now necessary to follow up children treated with ACTs
for 42 days in order to detect and ensure that children
with LAA recover from it. Thus, LAA may have practical
implications in endemic areas where ACTs have become
first-line treatments for uncomplicated malaria and where
anaemia is a significant contributor to morbidity.
There limitations of the present study, in particular with
late-appearing anaemia. These include non-characterization
of the haemolytic nature of the late-appearing anaemia
and non-evaluation of the contributions of background
causes of anaemia in this endemic area to the late-
appearing anaemia.
Conclusion
This study found that AA and AL are both efficacious
treatments for uncomplicated falciparum malaria in
Nigerian children aged 2 years but therapeutic responses
to the two ACTs are not uniform across the age band
6–59 months. Both treatments may cause a relatively
asymptomatic LAA with uneventful recovery in a small
proportion of very young children.
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